Blogs

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Forex

<p>Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of p

Signing Day Sports Announces New AI Initiatives Designed to Accelerate Customer Acquisition, Streamline the Application Process, Verify User Metrics, and Better Place Student Athletes

Forex

<p>SCOTTSDALE, AZ, Dec. 14, 2023 (GLOBE NEWSWIRE) — Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced a series of new artificial intelligence (AI) initiatives, designed to

Page 1288 of 9786